A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.

NCT00460850 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

60

Enrollment

INDUSTRY

Sponsor class

Stopped Low recruitment rate due to treatment regimen change

Conditions

Hepatitis B, Chronic

Interventions

DRUG: peginterferon alfa-2a (40KD) [PEGASYS]

Sponsor

Hoffmann-La Roche